Lamictal XR Approved
Published: 1 year, 1 month ago (Jun 1, 2009) in MedicalTags: drugs · Print This Post · Leave a Comment
Those with stakes in GlaxoSmithKline (NYSE: GSK) were pleased this morning as the stock rose on account of the FDA’s approval of Lamictal XR (“extended release”) . The drug, aimed at epilepsy patients thirteen years of age and older, is intended to reduce seizures in patients who have had unsuccessful results with other therapies.
Similar Posts:
Share This Post:
Published: 1 year, 1 month ago
Not to mention that GlaxoSmithKline markets Relenza (Zanamivir), effective against A H1N1 (previously known as swine flu) and which is almost as good as Roche’s Tamiflu.